Invited Review

Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome

Volume 36 · Issue Supplement 2 Publish Date: November 25, 2025
Full Text PDF
DOI
Serhat Bor ORCID
Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Türkiye
Hasan Özen ORCID
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hacettepe University Faculty of Medicine, Ankara, Türkiye
İsmail Hakkı Kalkan ORCID
Department of Gastroenterology, TOBB University of Economics and Technology School of Medicine, Ankara, Türkiye
Filiz Akyüz ORCID
Department of Gastroenterology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye
Altay Çelebi ORCID
Department of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Türkiye
Dinç Dinçer ORCID
Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Türkiye
Yusuf Serdar Sakin ORCID
Department of Gastroenterology, Acıbadem Kent Hospital, İzmir, Türkiye
Bor, S., Özen, H., Kalkan, İsmail H., Akyüz, F., Çelebi, A., Dinçer, D., & Sakin, Y. S. (2025). Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome. Turkish Journal of Gastroenterology, 36(Supplement 2), S1-S38. https://doi.org/10.5152/tjg.2025.101125
Full Text FULL TEXT PDF

Abstract

Antispasmodics are commonly used to treat irritable bowel syndrome (IBS) symptoms. They are generally regarded as safe.However, some have been found to be ineffective or not cost-effective. Marked discrepancies in the availability and formulation of antispasmodic agents across countries—ranging from the limitation to only fundamental compounds in regions such as the United States to the marketing of diverse combination products elsewhere—have generated considerable ambiguity and debate within the field. Meta-analyses show varying results on the efficacy of antispasmodics, indicating the need for further analysis. This article aims to evaluate the effectiveness of antispasmodic drugs in relieving symptoms in IBS patients. We conclude that most drugs are considered safe and effective, with pinaverium, otilonium, and peppermint oil having meta-analyses supporting their efficacy. However, there is a lack of high-quality data for drugs like alverine, trimebutine, and cimetropium, and some drugs, such as simeticone or combinations of spasmolytic agents and simeticone, have insufficient research data. Clinicians should prioritize evidence-based medicine when selecting antispasmodic agents.

 

Cite this article as: Bor S, Özen H, Akyüz F, et al. Expert opinion on the efficacy and safety of antispasmodics with a focus on irritable bowel syndrome. Turk J Gastroenterol. 2025;36(Supp 2):S1-S38.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 13 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 36 · Issue Supplement 2
Pages S1-S38
History
Published Online November 25, 2025
License
Copyright
Affiliations
Serhat Bor ORCID
Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Türkiye
Hasan Özen ORCID
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hacettepe University Faculty of Medicine, Ankara, Türkiye
İsmail Hakkı Kalkan ORCID
Department of Gastroenterology, TOBB University of Economics and Technology School of Medicine, Ankara, Türkiye
Filiz Akyüz ORCID
Department of Gastroenterology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye
Altay Çelebi ORCID
Department of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Türkiye
Dinç Dinçer ORCID
Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Türkiye
Yusuf Serdar Sakin ORCID
Department of Gastroenterology, Acıbadem Kent Hospital, İzmir, Türkiye
Cite this Article
Bor, S., Özen, H., Kalkan, İsmail H., Akyüz, F., Çelebi, A., Dinçer, D., & Sakin, Y. S. (2025). Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome. Turkish Journal of Gastroenterology, 36(Supplement 2), S1-S38. https://doi.org/10.5152/tjg.2025.101125
Outlines